Premium
Latent Tuberculosis Infection and BCG Vaccination
Author(s) -
Ross Lisa,
Goff Meredith
Publication year - 2005
Publication title -
journal of midwifery and women's health
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.543
H-Index - 62
eISSN - 1542-2011
pISSN - 1526-9523
DOI - 10.1016/j.jmwh.2005.03.003
Subject(s) - tuberculosis , latent tuberculosis , medicine , vaccination , mycobacterium tuberculosis , bcg vaccine , disease , public health , population , immunology , pregnancy , environmental health , pathology , biology , genetics
One third of the world's population is infected with Mycobacterium tuberculosis , and 5% to 10% of those infected will develop active disease. Identification and treatment of latent tuberculosis infection (LTBI) is an essential part of the public health strategy to control the spread of TB. The prenatal period provides an opportunity for obstetric providers to assist in this effort by offering testing and treatment to women at risk. J Midwifery Womens Heal
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom